UNSPSC 51283802: Pristinamycin or pristinamycine

This classification denotes an antibiotic with the molecular formula C34H50N4O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9M4FJE48E, chemically known as virginiamycin m1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26r,27s)- but generally known as dalfopristin, which bears US NIH Compound Identifier 6323289. European Medicines Agency schedules Dalfopristin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06892MIG.

The term DALFOPRISTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DALFOPRISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1C2N(CC1)C(=O)C1NC(OC1)CC(=O)CC(O)C=C(C=CCNC(=O)C=CC(C(OC2=O)C(C)C)C)C)CCN(CC)CC.

UNSPSC 51283802 Pristinamycin or pristinamycine is a Commodity code that bears little relationship to the state and local procurement activity tagged under it in recent solicitations. The code nominally describes a single pharmaceutical compound, but the recent opportunities posted under this code span naloxone procurement, emergency medical supplies for fire departments, generic pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs — none of which involve pristinamycin specifically. State and local governments do not appear to be buying pristinamycin as a standalone product through formal competitive solicitations at present.

The mismatch between the code name and actual solicitation scope reflects a tagging anomaly rather than a meaningful market signal. The opportunities listed — including Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023); the City of Tampa's ITB for medical and first aid supplies for the Fire Department Rescue Division (estimated at $700,000, due March 13, 2026, with SLBE set-asides); the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026); and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026) — indicate active procurement in broader pharmaceutical supply categories, but not in the specific compound this code nominally describes. Business development professionals should verify the actual UNSPSC codes under which their pharmaceutical products are being solicited, as this code does not reflect current state and local demand.